Microbiome Research Emerges as Key Complement to GLP-1 Therapies in Obesity Care

A new report from Seventure Partners highlights the growing role of the gut microbiome in shaping future obesity treatments, positioning microbiome science as a powerful complement to current drug-based approaches.

In Microbiome & Obesity: A Seventure Perspective on the Next Healthcare Frontier, Isabelle de Cremoux, CEO of Seventure Partners, examines how microbiome research could support more sustainable and personalized obesity management. With more than one billion people worldwide living with obesity and global economic costs projected to reach $4.32 trillion annually by 2035, new strategies are urgently needed.

While GLP-1 agonists have transformed obesity care and are expected to generate a $105 billion market by 2030, the report notes several limitations, including treatment discontinuation, gastrointestinal side effects, muscle mass loss and dependence on continued medication use.

Research increasingly shows that the gut microbiome can influence metabolic regulation. Microbial metabolites such as short-chain fatty acids can stimulate natural GLP-1 secretion, suggesting microbiome-targeted interventions could activate similar metabolic pathways through physiological mechanisms.

The report outlines emerging therapeutic categories including live biotherapeutics, next-generation probiotics, microbiome restoration therapies and functional fibers. It also emphasizes the importance of personalized approaches based on individual microbiome profiles.

According to Seventure Partners, integrating pharmacological treatments with microbiome-based solutions may represent the next major step toward precision medicine in obesity care.